IMM 0.00% 32.0¢ immutep limited

Ann: Immutep enters into collaboration with MSD, page-33

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 25,498 Posts.
    lightbulb Created with Sketch. 1388
    @theoc, yeah mate, very sketchy collaboration.....couple of interesting points....
    1....we retain Efti license.....very important for us good guys.
    2...US trials mooted yet immutep hasn't been approved to conduct US trials as yet....
    3....Does that mean trial conducted under Merck license?
    4...Ridgeback and Lucy up the anti a bit, thus making it harder for a hostile takeover.
    Nasdaq likely to take Holman's "renewed" interest favourably.
    5....Merck interest will go very well in the biotech industry, expect some very positive
    news items in the next few days...
    6....You would have to think that Merck interest is because of Tacti-mel, a
    Prima biomed/Immutep iniative where phase 1 results are imminent..In my
    mind that means Tactimel will progress to ph2....

    Take what I say with a grain of salt......
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
32.0¢
Change
0.000(0.00%)
Mkt cap ! $465.4M
Open High Low Value Volume
32.0¢ 32.0¢ 31.5¢ $547.1K 1.721M

Buyers (Bids)

No. Vol. Price($)
8 72820 31.5¢
 

Sellers (Offers)

Price($) Vol. No.
32.0¢ 49499 1
View Market Depth
Last trade - 16.10pm 11/10/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.